arbekacin

Arbekacin is a semisynthetic aminoglycoside antibiotic derived from dibekacin and classified within the kanamycin family. It is primarily used for the treatment of infections caused by multi-resistant bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA), as well as certain multidrug-resistant Gram-negative pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii. Arbekacin acts by irreversibly binding to the bacterial 30S ribosomal subunit, specifically interacting with four nucleotides of 16S rRNA and one amino acid of protein S12, thereby interfering with the decoding site around nucleotide 1400 in the 16S subunit. This leads to misreading of mRNA during translation, resulting in nonfunctional or toxic proteins that inhibit bacterial growth. The drug is not inactivated by common aminoglycoside-inactivating enzymes and demonstrates synergistic effects when combined with beta-lactam antibiotics[1][2][3][5][6].

Brand names

Habekacin

Other names

arbekacinahaberacinarbekacinearbekacinum